“Breyanzi represents a remarkable advance over a nearly 30-year standard of care, providing significantly improved efficacy with a well-established safety profile,” Manali Kamdar, lead investigator of the TRANSFORM study and clinical director of lymphoma services in the division of hematology, hematologic malignancies and stem cell transplantation at University of Colorado Cancer Center, said in a Bristol Myers Squibb-issued press release.